BRPI0607839A2 - compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos - Google Patents

compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos

Info

Publication number
BRPI0607839A2
BRPI0607839A2 BRPI0607839-7A BRPI0607839A BRPI0607839A2 BR PI0607839 A2 BRPI0607839 A2 BR PI0607839A2 BR PI0607839 A BRPI0607839 A BR PI0607839A BR PI0607839 A2 BRPI0607839 A2 BR PI0607839A2
Authority
BR
Brazil
Prior art keywords
compounds
propan
benzyl
amino
pyrimidin
Prior art date
Application number
BRPI0607839-7A
Other languages
English (en)
Inventor
Michael Patrick Pence
George Chang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0607839A2 publication Critical patent/BRPI0607839A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS 1,1,1-TRIFLúOR-3-[(BENZIL)-(PIRIMIDINI2-IL)-AMINO]-PROPAN- 2-OL SUBSTITUìDOS. Compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)amino]-propan-2-ol substituídos, composições farmacêuticas contendo tais compostos e uso de tais compostos para elevar determinados níveis de lipídeos no plasma, incluindo colesterol-lípoproteina de alta densidade e para abaixar determinados outros níveis de lípideo no plasma, tais como colesterol LDL e triglícerideos e conseqUentemente para tratar doenças que são exacerbadas por níveis baixos de colesterol HDL e/ou níveis altos de colesterol LDL e tríglícerídeos, tais como, aterosclerose e doenças cardiovasculares em alguns mamíferos, incluindo seres humanos.
BRPI0607839-7A 2005-02-23 2006-02-13 compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos BRPI0607839A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65574005P 2005-02-23 2005-02-23
PCT/IB2006/000374 WO2006090250A1 (en) 2005-02-23 2006-02-13 Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-prop an-2-ol compounds

Publications (1)

Publication Number Publication Date
BRPI0607839A2 true BRPI0607839A2 (pt) 2009-06-13

Family

ID=36215578

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607839-7A BRPI0607839A2 (pt) 2005-02-23 2006-02-13 compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos

Country Status (13)

Country Link
US (1) US20100130784A1 (pt)
EP (1) EP1856060A1 (pt)
JP (1) JP2008545617A (pt)
KR (1) KR20070096041A (pt)
CN (1) CN101128438A (pt)
AU (1) AU2006217630A1 (pt)
BR (1) BRPI0607839A2 (pt)
CA (1) CA2598869A1 (pt)
IL (1) IL184677A0 (pt)
MX (1) MX2007010243A (pt)
RU (1) RU2007131537A (pt)
WO (1) WO2006090250A1 (pt)
ZA (1) ZA200705972B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
US20120179035A1 (en) * 2011-01-07 2012-07-12 General Electric Company Medical device with motion sensing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3924124B2 (ja) * 1998-09-25 2007-06-06 ファルマシア・コーポレーション コレステロールエステル輸送タンパク質活性阻害に有効な置換された多環アリールおよびヘテロアリール第三級ヘテロアルキルアミン

Also Published As

Publication number Publication date
CA2598869A1 (en) 2006-08-31
AU2006217630A1 (en) 2006-08-31
US20100130784A1 (en) 2010-05-27
EP1856060A1 (en) 2007-11-21
ZA200705972B (en) 2009-02-25
CN101128438A (zh) 2008-02-20
WO2006090250A1 (en) 2006-08-31
MX2007010243A (es) 2007-09-07
KR20070096041A (ko) 2007-10-01
RU2007131537A (ru) 2009-03-27
IL184677A0 (en) 2007-12-03
JP2008545617A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
BRPI0518476A2 (pt) compostos e derivados de dibenzil amina
BR0207285A (pt) Agonistas de ppar
BRPI0408897A (pt) derivados de 1,2,3,4-tetrahidro-e 1,2-dihidro-quinolina 1,2,4-substituìdos como inibidores de cetp para o tratamento de arteroesclerose e obesidade
BRPI0410479A (pt) derivados de tetraidroisoquinolina como ativadores do ppar-(alfa)
CR6310A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas
BR0316521A (pt) Ativadores de ppar
PA8539101A1 (es) Compuestos de ppar
CR6306A (es) 1,2,3,4-tetrahidroquinlinas 2-sustituidas 4-amino sustituidas
BRPI0512624A (pt) compostos heteroarila e fenilsulfamoìla substituìdos
GT200300021A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
MY121838A (en) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
DOP2007000044A (es) Compuestos y derivados de dibencilamina
CR11272A (es) Enzimas de aciltranferasa de lecitina-colesterol, modificadas
CR9012A (es) Compuestos de 4-amino-sustituido-2-sustituido-1,2,3,4-tetrahidroquinolina
BRPI0607839A2 (pt) compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos
TW200806293A (en) Methods of treatment with CETP inhibitors
NO20083641L (no) Dibenzylaminforbindelser, samt derivater derav
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
BRPI0608061A2 (pt) método para abaixar os nìveis no sangue circulante de um lipìdio selecionado do grupo que consiste em colesterol ldl, triglicerìdios, colesterol total, e as misturas destes e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons
DOP2003000762A (es) Activadores de ppar
PA8589501A1 (es) Activadores de ppar
ECSP993135A (es) 1,2,3,4- tetrahidroquinolinas -2 -sustituidas 4- amino sustituidas
DOP2002000327A (es) Agonistas de ppar
ECSP993134A (es) 1,2,3,4- tetrahidroquinolinas -2 -sustituidas 4- carboxiamino sustituidas
SV2006002314A (es) Compuestos y derivados de dibencil amina ref. no. pc32592a

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.